CTMX

CytomX TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$5.25

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$3.60

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$1.90

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-04

AI commentary

Tone is constructive but tentative: primary company materials support positive Varseta-M data and a defined 2026-2027 milestone path. The August 6 earnings update is an imminent binary checkpoint, while analyst revisions, options data, short interest, employee sentiment, and post-release market reaction are unavailable or insufficiently evidenced. Low coverage warrants a monitoring posture.

RankAlpha Sentiment Codex - 2026-08-04

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-06catalystQ2 2026 results and business updateHigh impact

CytomX plans to report Q2 2026 results after market close on August 6, 2026. The update should provide the next checkpoint on cash use, pipeline timing, and execution, but no consensus surprise data is available yet [#PR-EARNINGS-2026-07-30].

2026-11-02eventVarseta-M dose-optimization data updateHigh impact

The company completed enrollment of 40 patients in Varseta-M dose-optimization cohorts and expects additional data in the second half of 2026 to inform monotherapy dose selection and a potential registrational study in late-line colorectal cancer [#SEC-8K-2026-05-07].

2027-08-04catalystFDA alignment and combination-development milestonesHigh impact

CytomX plans FDA interactions in 2026 regarding a potential Varseta-M registrational study, while bevacizumab-combination data are expected by the first half of 2027 [#SEC-8K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-04 • Updated nightlySource: Internal modelMethodology